Dec 6, 2012
NCT01668719: Phase 1/2 - S1211 Bort, Dex & Lenalidomide +/- Elotuzumab High Risk NDMM SWOG 1211
SWOG 1211 S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed...
152
Dec 5, 2012
FDA Approved for Multiple Myeloma treatment: Bortezomib (formerly PS-341) VELCADE SUBCUTANEOUSLY
01/23/2012: FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications CAMBRIDGE, Mass.--(BUSINESS...
114
Dec 16, 2011
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
NCT01464034: Phase 1/2: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or...
148
Dec 16, 2011
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With RRMM Myeloma
NCT01410500: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease NCT01410500:...
40
Dec 9, 2011
NCT01311687: Phase 3 - Efficacy & Safety of Pomalidomide & Low dose dex Vs High-Dose Dex - NIMBUS
MM-003 The NIMBUS trial The purpose of this study is to compare efficacy and safety of pomalidomide in combination with low-dose...
323
Dec 9, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
842
Dec 8, 2011
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients
NCT01402284: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients KRd Carfilzomib is an experimental...
137
Dec 7, 2011
NCT01346787: EMN - Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone Newly Diagnosed Myeloma
EMN European Myeloma Network NCT01346787: Phase 2: Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma...
68
Dec 3, 2011
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness
NCT01421524: Phase 1: Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors,...
148
Dec 1, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib...
61
Dec 18, 2010
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry
NCT01081028: Connect® MM- The Multiple Myeloma Disease Registry The purpose of the Connect® MM Registry is to explore the natural history...
368
Dec 18, 2010
NCT01239797: Phase 3: Lenalidomide and Dexamethasone With or Without Elotuzumab RRMM (ELOQUENT - 2)
ELOQUENT - 2 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple...
100
Dec 18, 2010
NCT01208766: Phase 3 - EMN02 - Compare VMP With HDM f/b VRD Consol & Lenalidomide Maint. NDMM (HO95)
The EMN02/HOVON95 trial (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study Study to Compare VMP With HDM Followed by VRD...
196
Dec 17, 2010
GMMG phase III trial ReLApsE Salvage autologous transplant and lenalidomide maintenance vs. len-Dex
Time Frame: 2010 and 2016 Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple...
59
Dec 16, 2010
NCT01093196: Phase 3: EMN01- Len/Dex Vs Melphalan/Pred/Len Vs Cyclophosamide/Pred/Len - elderly NDMM
EMN01 European Myeloma Network Newly Diagnosed Multiple Myeloma NCT01093196: Phase 3: Len and Dex Vs Melphalan Prednisone and Len Vs...
183
Dec 16, 2010
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide & Low-Dose Dexamethasone in RRMM Myeloma
NCT01155583: Phase 1/2: Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma...
73
Dec 11, 2010
NCT01208662- Phase 3 - DETERMINATION Trial: Delayed vs Early Transplant with RVd & Revlimid Maint.
NDMM - DFCI 10-106 DETERMINATION Trial Delayed vs Early Transplant with Revlimid Maintenance and Anti-Myeloma Triple Therapy DFCI 10-106...
1,125
Dec 10, 2010
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
536
Dec 10, 2010
NCT01169337: Phase 3 -Lenalidomide or Observation in Asymptomatic High-Risk Smoldering Myeloma E3A06
ECOG E3A06 ECOG-ACRIN Cancer Research Group ECOG E3A06 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk...
202
Dec 9, 2010
NCT01134484: Phase 3 - VELCADE-Thal-Dex (VTD) vs Thal-Dex (TD) Incorporated Into Double ASCT NDMM
GIMEMA-MMY-3006 Study GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network). VELCADE-Thalidomide-Dexametha...
110
Dec 9, 2010
NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maint. NDMM BMT CTN 0702 (STaMINA)
STaMINA Trial BMT CTN 0702 NCT01109004: Phase 3 - Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma...
183
Dec 7, 2010
NCT01217957: Phase 1/2: A Study of Ixazomib in Combination With Lenalidomide and Low-Dex in NDMM
NCT01217957: Phase 1/2: A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With...
73
Dec 3, 2010
NCT01191060: Phase 3 - IFM 2009 - (IFM/DFCI2009) Conventional dose RVD to High-Dose + ASCT -NDMM
IFM 2009 IFM/DFCI2009 The Intergroupe Francophone du Myelome 2009 trial Study Comparing Conventional Dose Combination RVD to High-Dose...
441
Dec 3, 2010
NCT01190787: Phase 2: EMN - Velcade/Melphalan/Pred or Velcade/Cycloposphamide/Pred or Velcade/Pred.
EMN - European Myeloma Network Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus...
159